Publications in collaboration with researchers from Hôpital Européen Georges-Pompidou (12)

2023

  1. Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 42-53

2022

  1. Characterization of atrial fibrillation in real-world patients: testing the 4S-AF scheme in the Spanish and French cohorts of the EORP-AF Long-Term General Registry

    Europace, Vol. 24, Núm. 2, pp. 202-210

2021

  1. A Primary Prevention Clinical Risk Score Model for Patients With Brugada Syndrome (BRUGADA-RISK)

    JACC: Clinical Electrophysiology, Vol. 7, Núm. 2, pp. 210-222

  2. Prospective follow-up in various subtypes of cardiomyopathies: Insights from the ESC EORP Cardiomyopathy Registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 7, Núm. 2, pp. 134-142

  3. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: The results of the AFFIRM-AHF study

    European Heart Journal, Vol. 42, Núm. 31, pp. 3011-3020

2020

  1. An expert consensus document on the management of cardiovascular manifestations of Fabry disease

    European Journal of Heart Failure, Vol. 22, Núm. 7, pp. 1076-1096

  2. Factors influencing the use of leadless or transvenous pacemakers: Results of the European Heart Rhythm Association Prospective Survey

    Europace, Vol. 22, Núm. 4, pp. 667-673

  3. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

    The Lancet, Vol. 396, Núm. 10266, pp. 1895-1904

2019

  1. International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)

    Thrombosis Journal, Vol. 17, Núm. 1

2018

  1. Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey)

    American Journal of Cardiology, Vol. 122, Núm. 4, pp. 578-583

2008

  1. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: Follow-up of the Euro Heart Survey on Atrial Fibrillation

    European Heart Journal, Vol. 29, Núm. 9, pp. 1181-1189

2005

  1. Atrial fibrillation management: A prospective survey in ESC Member Countries - The Euro Heart Survey on atrial fibrillation

    European Heart Journal, Vol. 26, Núm. 22, pp. 2422-2434